Acumen Pharmaceuticals (ABOS) Cash on Hand

Price: $1.13
Market Cap: $68.45M
Avg Volume: 238.57K
Country: US
Industry: Biotechnology
Sector: Healthcare
Beta: 0.098
52W Range: $0.855-3.92
Website: Acumen Pharmaceuticals
How much cash does Acumen Pharmaceuticals have?

According to Acumen Pharmaceuticals's latest annual financial reports, the company has a total of $35.63M in cash and cash equivalents. This amount includes all liquid assets that can be readily converted into cash.

Additionally, Acumen Pharmaceuticals holds $135.93M in short-term investments, which are highly liquid assets that can be easily converted into cash within a short period.

In total, the company has $171.56M when combining cash and cash equivalents with short-term investments.

On a per-share basis, Acumen Pharmaceuticals has $2.86 in cash. This metric helps investors understand how much cash the company holds per outstanding share.

The company's free cash flow, which is the cash generated from operations after deducting capital expenditures, stands at $-86.23M. This is an important indicator of financial health, showing the cash available for distribution to shareholders or reinvestment into the company.

Lastly, the company's cash position has experienced a growth rate of -46.73%, reflecting the increase in cash and cash equivalents over the specified period.

Cash & Cash Equivalents

$35.63M

Short-Term Investments

$135.93M

Cash & Short-Term Investments

$171.56M

Cash Per Share

$2.86

Free Cash Flow

$-86.23M

Cash Growth

-46.73%

Acumen Pharmaceuticals Historical Cash on Hand
$150.00M$150.00M$120.00M$120.00M$90.00M$90.00M$60.00M$60.00M$30.00M$30.00M$0.00$0.00Cash on Hand2020202020212021202220222023202320242024
Cash on Hand History

The table below shows the amount of cash on hand for each year, with the latest data available for the last fiscal year 2024.

Year Cash on Hand Change
2024 $35.63M -46.73%
2023 $66.89M -48.59%
2022 $130.10M 6.50%
2021 $122.16M 179.06%
2020 $43.78M 568.15%
2019 $6.55M N/A

Related Metrics

Explore detailed financial metrics and analysis for ABOS.